Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 314

1.

[18F]GTP1 (Genentech Tau Probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer's disease.

Sanabria Bohórquez S, Marik J, Ogasawara A, Tinianow JN, Gill HS, Barret O, Tamagnan G, Alagille D, Ayalon G, Manser P, Bengtsson T, Ward M, Williams SP, Kerchner GA, Seibyl JP, Marek K, Weimer RM.

Eur J Nucl Med Mol Imaging. 2019 Jun 28. doi: 10.1007/s00259-019-04399-0. [Epub ahead of print]

PMID:
31254035
2.

Concordance for Parkinson's disease in twins: A 20-year update.

Goldman SM, Marek K, Ottman R, Meng C, Comyns K, Chan P, Ma J, Marras C, Langston JW, Ross GW, Tanner CM.

Ann Neurol. 2019 Apr;85(4):600-605. doi: 10.1002/ana.25441. Epub 2019 Mar 11.

PMID:
30786044
3.

Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI).

Prakash N, Caspell-Garcia C, Coffey C, Siderowf A, Tanner CM, Kieburtz K, Mollenhauer B, Galasko D, Merchant K, Foroud T, Chahine LM, Weintraub D, Casaceli C, Dorsey R, Wilson R, Herzog M, Daegele N, Arnedo V, Frasier M, Sherer T, Marek K, Frank S, Jennings D, Simuni T; Parkinson's Progression Markers InitiativeSteering Committee; Study Cores; Site Investigators; Coordinators; Industry and Scientific Advisory Board.

Parkinsonism Relat Disord. 2019 May;62:201-209. doi: 10.1016/j.parkreldis.2018.12.025. Epub 2019 Jan 31.

PMID:
30738748
4.

Molecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson's Disease.

Romero K, Conrado D, Burton J, Nicholas T, Sinha V, Macha S, Ahamadi M, Cedarbaum J, Seibyl J, Marek K, Basseches P, Hill D, Somer E, Gallagher J, Dexter DT, Roach A, Stephenson D; Critical Path for Parkinson's (CPP) Consortium; Parkinson's Progression Markers Initiative (PPMI).

Clin Transl Sci. 2019 May;12(3):240-246. doi: 10.1111/cts.12619. Epub 2019 Mar 18.

5.

Basic clinical features do not predict dopamine transporter binding in idiopathic REM behavior disorder.

Chahine LM, Iranzo A, Fernández-Arcos A, Simuni T, Seedorff N, Caspell-Garcia C, Amara AW, Comella C, Högl B, Hamilton J, Marek K, Mayer G, Mollenhauer B, Postuma R, Tolosa E, Trenkwalder C, Videnovic A, Oertel W; PPMI Sleep Working Group.

NPJ Parkinsons Dis. 2019 Jan 29;5:2. doi: 10.1038/s41531-018-0073-1. eCollection 2019.

6.

The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort.

Marek K, Chowdhury S, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Simuni T, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun-Turgut D, Poston K, Arnedo V, Frasier M, Sherer T; Parkinson's Progression Markers Initiative.

Ann Clin Transl Neurol. 2018 Oct 31;5(12):1460-1477. doi: 10.1002/acn3.644. eCollection 2018 Dec.

7.

Effects of Treatment with Crizotinib on Non-small Cell Lung Carcinoma with ALK Translocation in the Czech Republic.

Miloš P, Jana S, Vítězslav K, Monika Š, Leona K, Jaromír R, Renata C, Markéta Č, Andrea B, Juraj K, Michal H, Milada Z, Marek K, Helena Č, Martin S.

Klin Onkol. Spring 2018;31(3):207-212. doi: 10.14735/amko2018207.

PMID:
30441974
8.

123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson's disease cohort versus Parkinson's disease.

Koros C, Simitsi A, Prentakis A, Beratis I, Papadimitriou D, Kontaxopoulou D, Fragkiadaki S, Papagiannakis N, Seibyl J, Marek K, Papageorgiou SG, Trapali XG, Stamelou M, Stefanis L.

Mov Disord. 2018 Nov;33(11):1734-1739. doi: 10.1002/mds.27451. Epub 2018 Oct 4.

PMID:
30288781
9.

Movement disorder society criteria for clinically established early Parkinson's disease.

Berg D, Adler CH, Bloem BR, Chan P, Gasser T, Goetz CG, Halliday G, Lang AE, Lewis S, Li Y, Liepelt-Scarfone I, Litvan I, Marek K, Maetzler C, Mi T, Obeso J, Oertel W, Olanow CW, Poewe W, Rios-Romenets S, Schäffer E, Seppi K, Heim B, Slow E, Stern M, Bledsoe IO, Deuschl G, Postuma RB.

Mov Disord. 2018 Oct;33(10):1643-1646. doi: 10.1002/mds.27431. Epub 2018 Aug 25.

PMID:
30145841
10.

Finding useful biomarkers for Parkinson's disease.

Chen-Plotkin AS, Albin R, Alcalay R, Babcock D, Bajaj V, Bowman D, Buko A, Cedarbaum J, Chelsky D, Cookson MR, Dawson TM, Dewey R, Foroud T, Frasier M, German D, Gwinn K, Huang X, Kopil C, Kremer T, Lasch S, Marek K, Marto JA, Merchant K, Mollenhauer B, Naito A, Potashkin J, Reimer A, Rosenthal LS, Saunders-Pullman R, Scherzer CR, Sherer T, Singleton A, Sutherland M, Thiele I, van der Brug M, Van Keuren-Jensen K, Vaillancourt D, Walt D, West A, Zhang J.

Sci Transl Med. 2018 Aug 15;10(454). pii: eaam6003. doi: 10.1126/scitranslmed.aam6003. Review.

PMID:
30111645
11.

Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers.

Constantinescu CC, Tresse C, Zheng M, Gouasmat A, Carroll VM, Mistico L, Alagille D, Sandiego CM, Papin C, Marek K, Seibyl JP, Tamagnan GD, Barret O.

Mol Imaging Biol. 2019 Jun;21(3):509-518. doi: 10.1007/s11307-018-1260-5.

PMID:
30084043
12.

The need for mapping personal goals to exercise dosage in community-based exercise programs for people with Parkinson's disease.

Amateis AL, Boesel CL, Ehnert BP, Evans AS, Hurst KE, Marek KL, Sullivan AC, Zalewski KR, Huddleston WE.

Physiother Theory Pract. 2018 May 23:1-9. doi: 10.1080/09593985.2018.1476942. [Epub ahead of print]

PMID:
29791244
13.

Plasma α-synuclein and cognitive impairment in the Parkinson's Associated Risk Syndrome: A pilot study.

Wang H, Atik A, Stewart T, Ginghina C, Aro P, Kerr KF, Seibyl J, Jennings D; PARS Investigators, Jensen PH, Marek K, Shi M, Zhang J.

Neurobiol Dis. 2018 Aug;116:53-59. doi: 10.1016/j.nbd.2018.04.015. Epub 2018 Apr 27.

PMID:
29705185
14.

Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort.

Simuni T, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun D, Poston K, Arnedo V, Frasier M, Sherer T, Chowdhury S, Marek K; Parkinson's Progression Marker Initiative*.

Mov Disord. 2018 May;33(5):771-782. doi: 10.1002/mds.27361. Epub 2018 Mar 23.

15.

Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18.

Devous MD Sr, Joshi AD, Navitsky M, Southekal S, Pontecorvo MJ, Shen H, Lu M, Shankle WR, Seibyl JP, Marek K, Mintun MA.

J Nucl Med. 2018 Jun;59(6):937-943. doi: 10.2967/jnumed.117.200691. Epub 2017 Dec 28.

16.

Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.

Wilcock GK, Gauthier S, Frisoni GB, Jia J, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Schelter BO, Wischik DJ, Davis CS, Staff RT, Vuksanovic V, Ahearn T, Bracoud L, Shamsi K, Marek K, Seibyl J, Riedel G, Storey JMD, Harrington CR, Wischik CM.

J Alzheimers Dis. 2018;61(1):435-457. doi: 10.3233/JAD-170560.

17.

Observations on a 2-Step Approach to Screening for Parkinson Disease-Reply.

Jennings D, Siderowf A, Marek K.

JAMA Neurol. 2017 Dec 1;74(12):1506-1507. doi: 10.1001/jamaneurol.2017.3208. No abstract available.

PMID:
29114721
18.

Cognition and the course of prodromal Parkinson's disease.

Weintraub D, Chahine LM, Hawkins KA, Siderowf A, Eberly S, Oakes D, Seibyl J, Stern MB, Marek K, Jennings D; PARS Investigators.

Mov Disord. 2017 Nov;32(11):1640-1645. doi: 10.1002/mds.27189. Epub 2017 Oct 24.

19.

Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls.

Mollenhauer B, Caspell-Garcia CJ, Coffey CS, Taylor P, Shaw LM, Trojanowski JQ, Singleton A, Frasier M, Marek K, Galasko D; Parkinson's Progression Marker Initiative.

Neurology. 2017 Nov 7;89(19):1959-1969. doi: 10.1212/WNL.0000000000004609. Epub 2017 Oct 13.

20.

Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort.

Simuni T, Caspell-Garcia C, Coffey CS, Weintraub D, Mollenhauer B, Lasch S, Tanner CM, Jennings D, Kieburtz K, Chahine LM, Marek K.

J Neurol Neurosurg Psychiatry. 2018 Jan;89(1):78-88. doi: 10.1136/jnnp-2017-316213. Epub 2017 Oct 6.

21.

Vitamin D in the Parkinson Associated Risk Syndrome (PARS) study.

Fullard ME, Xie SX, Marek K, Stern M, Jennings D, Siderowf A, Willis AW, Chen-Plotkin AS.

Mov Disord. 2017 Nov;32(11):1636-1640. doi: 10.1002/mds.27127. Epub 2017 Sep 14.

22.

Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Obeso JA, Stamelou M, Goetz CG, Poewe W, Lang AE, Weintraub D, Burn D, Halliday GM, Bezard E, Przedborski S, Lehericy S, Brooks DJ, Rothwell JC, Hallett M, DeLong MR, Marras C, Tanner CM, Ross GW, Langston JW, Klein C, Bonifati V, Jankovic J, Lozano AM, Deuschl G, Bergman H, Tolosa E, Rodriguez-Violante M, Fahn S, Postuma RB, Berg D, Marek K, Standaert DG, Surmeier DJ, Olanow CW, Kordower JH, Calabresi P, Schapira AHV, Stoessl AJ.

Mov Disord. 2017 Sep;32(9):1264-1310. doi: 10.1002/mds.27115. Review.

23.

Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease.

Eidson LN, Kannarkat GT, Barnum CJ, Chang J, Chung J, Caspell-Garcia C, Taylor P, Mollenhauer B, Schlossmacher MG, Ereshefsky L, Yen M, Kopil C, Frasier M, Marek K, Hertzberg VS, Tansey MG.

J Neuroinflammation. 2017 Aug 18;14(1):164. doi: 10.1186/s12974-017-0935-1.

24.

Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis.

Conrado DJ, Nicholas T, Tsai K, Macha S, Sinha V, Stone J, Corrigan B, Bani M, Muglia P, Watson IA, Kern VD, Sheveleva E, Marek K, Stephenson DT, Romero K; Critical Path for Parkinson's (CPP) Parkinson's Disease Modeling and Simulation Working Group.

Clin Transl Sci. 2018 Jan;11(1):63-70. doi: 10.1111/cts.12492. Epub 2017 Jul 27.

25.

Portable objective assessment of upper extremity motor function in Parkinson's disease.

Chahine LM, Uribe L, Hogarth P, McNames J, Siderowf A, Marek K, Jennings D.

Parkinsonism Relat Disord. 2017 Oct;43:61-66. doi: 10.1016/j.parkreldis.2017.07.017. Epub 2017 Jul 19.

PMID:
28747279
26.

A Bayesian mathematical model of motor and cognitive outcomes in Parkinson's disease.

Hayete B, Wuest D, Laramie J, McDonagh P, Church B, Eberly S, Lang A, Marek K, Runge K, Shoulson I, Singleton A, Tanner C, Khalil I, Verma A, Ravina B.

PLoS One. 2017 Jun 12;12(6):e0178982. doi: 10.1371/journal.pone.0178982. eCollection 2017.

27.

Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort.

Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, Marek K; PARS Investigators.

JAMA Neurol. 2017 Aug 1;74(8):933-940. doi: 10.1001/jamaneurol.2017.0985.

28.
29.

Longitudinal assessment of excessive daytime sleepiness in early Parkinson's disease.

Amara AW, Chahine LM, Caspell-Garcia C, Long JD, Coffey C, Högl B, Videnovic A, Iranzo A, Mayer G, Foldvary-Schaefer N, Postuma R, Oertel W, Lasch S, Marek K, Simuni T; Parkinson’s Progression Markers Initiative.

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):653-662. doi: 10.1136/jnnp-2016-315023. Epub 2017 May 29.

PMID:
28554959
30.

Contribution of PPARγ in modulation of acrolein-induced inflammatory signaling in gp91phox knock-out mice.

Yousefipour Z, Chug N, Marek K, Nesbary A, Mathew J, Ranganna K, Newaz MA.

Biochem Cell Biol. 2017 Aug;95(4):482-490. doi: 10.1139/bcb-2016-0198. Epub 2017 Apr 4.

PMID:
28376311
31.

The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies.

Pont-Sunyer C, Tolosa E, Caspell-Garcia C, Coffey C, Alcalay RN, Chan P, Duda JE, Facheris M, Fernández-Santiago R, Marek K, Lomeña F, Marras C, Mondragon E, Saunders-Pullman R, Waro B; LRRK2 Cohort Consortium.

Mov Disord. 2017 May;32(5):726-738. doi: 10.1002/mds.26964. Epub 2017 Mar 28.

PMID:
28370517
32.

Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials.

Fleisher AS, Joshi AD, Sundell KL, Chen YF, Kollack-Walker S, Lu M, Chen S, Devous MD Sr, Seibyl J, Marek K, Siemers ER, Mintun MA.

Alzheimers Dement. 2017 Oct;13(10):1117-1124. doi: 10.1016/j.jalz.2017.02.009. Epub 2017 Mar 30.

PMID:
28365320
33.

Kinetic Modeling of the Tau PET Tracer 18F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects.

Barret O, Alagille D, Sanabria S, Comley RA, Weimer RM, Borroni E, Mintun M, Seneca N, Papin C, Morley T, Marek K, Seibyl JP, Tamagnan GD, Jennings D.

J Nucl Med. 2017 Jul;58(7):1124-1131. doi: 10.2967/jnumed.116.182881. Epub 2016 Dec 1.

34.

Clinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: a US perspective.

Isaacson SH, Fisher S, Gupta F, Hermanowicz N, Kremens DE, Lew MF, Marek K, Pahwa R, Russell DS, Seibyl J.

Expert Rev Neurother. 2017 Mar;17(3):219-225. doi: 10.1080/14737175.2017.1256205. Epub 2016 Nov 23. Review.

PMID:
27813429
35.

Abolishing the 1-year rule: How much evidence will be enough?

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G.

Mov Disord. 2016 Nov;31(11):1623-1627. doi: 10.1002/mds.26796. Epub 2016 Sep 26. No abstract available.

PMID:
27666574
36.

Profiling Patient Characteristics Associated With the Intensity of Nurse Care Coordination.

Kim TY, Marek KD.

West J Nurs Res. 2017 Jan;39(1):186-203. doi: 10.1177/0193945916661493. Epub 2016 Sep 25.

37.

Predictors of time to initiation of symptomatic therapy in early Parkinson's disease.

Simuni T, Long JD, Caspell-Garcia C, Coffey CS, Lasch S, Tanner CM, Jennings D, Kieburtz KD, Marek K; PPMI Investigators.

Ann Clin Transl Neurol. 2016 May 17;3(7):482-94. doi: 10.1002/acn3.317. eCollection 2016 Jul.

38.

The new definition and diagnostic criteria of Parkinson's disease.

Postuma RB, Berg D, Adler CH, Bloem BR, Chan P, Deuschl G, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Oertel W, Olanow CW, Poewe W, Stern M.

Lancet Neurol. 2016 May;15(6):546-8. doi: 10.1016/S1474-4422(16)00116-2. Epub 2016 Apr 11. No abstract available.

PMID:
27302120
39.

Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease.

Lim NS, Swanson CR, Cherng HR, Unger TL, Xie SX, Weintraub D, Marek K, Stern MB, Siderowf A; PARS Investigators; Alzheimer's Disease Neuroimaging Initiative, Trojanowski JQ, Chen-Plotkin AS.

Ann Clin Transl Neurol. 2016 Mar 29;3(5):346-55. doi: 10.1002/acn3.299. eCollection 2016 May.

40.

How stable are Parkinson's disease subtypes in de novo patients: Analysis of the PPMI cohort?

Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Tanner C, Marek K; PPMI Investigators.

Parkinsonism Relat Disord. 2016 Jul;28:62-7. doi: 10.1016/j.parkreldis.2016.04.027. Epub 2016 Apr 23.

PMID:
27132498
41.

Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.

Vilas D, Shaw LM, Taylor P, Berg D, Brockmann K, Aasly J, Marras C, Pont-Sunyer C, Ríos J, Marek K, Tolosa E.

Mov Disord. 2016 Jun;31(6):906-14. doi: 10.1002/mds.26591. Epub 2016 Apr 4.

PMID:
27041685
42.

CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.

Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR, Irwin DJ, Van Deerlin V, Chen-Plotkin AS, Caspell-Garcia C, Waligórska T, Taylor P, Shah N, Pan S, Zero P, Frasier M, Marek K, Kieburtz K, Jennings D, Tanner CM, Simuni T, Singleton A, Toga AW, Chowdhury S, Trojanowski JQ, Shaw LM; Parkinson’s Progression Marker Initiative.

Acta Neuropathol. 2016 Jun;131(6):935-49. doi: 10.1007/s00401-016-1552-2. Epub 2016 Mar 28.

43.

Identifying Care Coordination Interventions Provided to Community-Dwelling Older Adults Using Electronic Health Records.

Kim TY, Marek KD, Coenen A.

Comput Inform Nurs. 2016 Jul;34(7):303-11. doi: 10.1097/CIN.0000000000000232.

44.

Comparing Aging in Place to Home Health Care: Impact of Nurse Care Coordination On Utilization and Costs.

Popejoy LL, Galambos C, Stetzer F, Popescu M, Hicks L, Khalilia MA, Rantz MJ, Marek KD.

Nurs Econ. 2015 Nov-Dec;33(6):306-13.

45.

Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging.

Russell DS, Jennings DL, Barret O, Tamagnan GD, Carroll VM, Caillé F, Alagille D, Morley TJ, Papin C, Seibyl JP, Marek KL.

Neurology. 2016 Feb 23;86(8):748-54. doi: 10.1212/WNL.0000000000002391. Epub 2016 Jan 22.

PMID:
26802091
46.

Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Individuals with Early Alzheimer's Disease: Amyloid Imaging Positron Emission Tomography and Safety Results from a Phase 2 Study.

van Dyck CH, Sadowsky C, Le Prince Leterme G, Booth K, Peng Y, Marek K, Ketter N, Liu E, Wyman BT, Jackson N, Slomkowski M, Ryan JM.

J Prev Alzheimers Dis. 2016;3(2):75-84. doi: 10.14283/jpad.2016.91.

PMID:
29210443
47.

Early Clinical Predictors of Treatment-Resistant and Functional Outcomes in Parkinson's Disease.

Kurlan R, Ravina B, Eberly S, Lang AE, Tanner CM, Marek K, Marder K, Beck J, Elliott R, Oakes D, Shoulson I; PSG PostCEPT (LABS‐PD) Investigators.

Mov Disord Clin Pract. 2015 Dec 14;3(1):53-58. doi: 10.1002/mdc3.12273. eCollection 2016 Jan-Feb.

48.

Preclinical properties and human in vivo assessment of 123I-ABC577 as a novel SPECT agent for imaging amyloid-β.

Maya Y, Okumura Y, Kobayashi R, Onishi T, Shoyama Y, Barret O, Alagille D, Jennings D, Marek K, Seibyl J, Tamagnan G, Tanaka A, Shirakami Y.

Brain. 2016 Jan;139(Pt 1):193-203. doi: 10.1093/brain/awv305. Epub 2015 Oct 21.

49.

MDS research criteria for prodromal Parkinson's disease.

Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G.

Mov Disord. 2015 Oct;30(12):1600-11. doi: 10.1002/mds.26431. Review.

PMID:
26474317
50.

MDS clinical diagnostic criteria for Parkinson's disease.

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G.

Mov Disord. 2015 Oct;30(12):1591-601. doi: 10.1002/mds.26424. Review.

PMID:
26474316

Supplemental Content

Support Center